Oxford Biomedica PLC Grant of options (5311U)
2023年11月24日 - 4:00PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDMOXB
RNS Number : 5311U
Oxford Biomedica PLC
24 November 2023
Grant of options
London, UK - 24 November 2023: Oxford Biomedica plc ("Oxford
Biomedica" or "the Company") (LSE: OXB), a quality and
innovation-led cell and gene therapy CDMO, announces that on 23
November 2023 nil-cost share options over Ordinary shares of 50
pence each in the Company were granted under the Oxford Biomedica
2015 Long Term Incentive Plan ("LTIP").
2023 LTIP Awards
Name of individual Title Number of Total shares Percentage of
shares subject over which current issued
to the 2023 options now share capital
LTIP award held under option
Chief Operating
Thierry Cournez Officer 66,437 66,437 0.069%
----------------- ---------------- ------------- ----------------
The LTIP awards are subject to performance conditions. As set
out in the 2022 Directors' Remuneration Report, the performance
condition is based on TSR (40% of the award, assessed over the
three years from grant); revenue growth (40% of the award, assessed
over financial years 2023, 2024 and 2025) and strategic milestones
(20% of the award).
The Notification of Dealing Forms set out below are provided in
accordance with the requirements of the EU Market Abuse
Regulation.
Notification of Dealing Form
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Thierry Cournez
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Chief Operating Officer
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument ISIN: GB00BDFBVT43
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan. No consideration was paid for
the grant of awards.
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 66,437
-------
----------------------------- -----------------------------------------
d) Aggregated information
* Aggregate volume Awards granted over 66,437 shares in
total
* Price N/A
----------------------------- -----------------------------------------
e) Date of the transaction 2023-11-23
----------------------------- -----------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- -----------------------------------------
-Ends-
For further information, please
contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell
and gene therapy CDMO with a mission to enable its clients to
deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the
Company has more than 25 years of experience in viral vectors; the
driving force behind the majority of gene therapies. The Company
collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV) and adenoviral vectors. Oxford
Biomedica's world-class capabilities span from early-stage
development to commercialisation. These capabilities are supported
by robust quality-assurance systems, analytical methods and depth
of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in
Oxford, UK. It has locations across Oxfordshire, UK and near
Boston, MA, US. Learn more at www.oxb.com , and follow us on
LinkedIn and YouTube .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDGBDBGUDDGXX
(END) Dow Jones Newswires
November 24, 2023 02:00 ET (07:00 GMT)
Oxford Biomedica (AQSE:OXB.GB)
過去 株価チャート
から 10 2024 まで 11 2024
Oxford Biomedica (AQSE:OXB.GB)
過去 株価チャート
から 11 2023 まで 11 2024
